Shafay meets world trade developers delegationSouth Korean authorities seek warrant to detain impeached President Yoon in martial law probeSouth Korea Industrial Output (YoY) below expectations (0.4%) in November: Actual (0.1%)
The IND vs AUS Boxing Day Test match has been a splendid showdown and it can be seen from the record number of fans who have turned up every day to watch the action live from the Melbourne Cricket Ground (MCG). The venue now has a new attendance record after a total of 51,371 fans (as recorded at 12:06 pm local time) showed up to watch Day 5 of the IND vs AUS 4th Test. As a result of this, the IND vs AUS Boxing Day Test at MCG now has seen a total of 3,50,700 fans attend over five days, which is the most at the venue, going past the total of 3,50,534, a record which was set during an Australia vs England match in 1937. IND vs AUS 4th Test in Border-Gavaskar Trophy 2024-25 at MCG Breaks Record of Largest Crowd In History to Attend Boxing Day Test . 🚨 ALL-TIME MCG TEST ATTENDANCE RECORD 🚨 We've officially surpassed the attendance record set in 1936/37 when Australia faced England — a Test which spanned six days! pic.twitter.com/Kykmz8KY65 — Melbourne Cricket Ground (@MCG) December 30, 2024 At 12.06pm local time, Cricket Australia announced an all-time record Test match crowd for the MCG. The attendance of 51,371 so far on day five takes the total to 350,700. This beats the total of 350,534 v England in January 1937, which was played over over six days #AUSvIND — Daniel Brettig 🏏 (@danbrettig) December 30, 2024 (SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter (X), Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)Martha Karua, the lead counsel in Ugandan opposition politician Kizza Besigye’s case following his abduction in Kenya, said on Monday her application for a temporary law practice certificate in the neighbouring country was turned down. Karua said the Ugandan Law Council declined her application in a letter dated December 6 because copies of her practising certificate and letter of good standing from the Law Society of Kenya were not notarized. Responding to the Ugandan Law Council in a letter she also shared on her social media accounts, Karua said the council told her that her nationality documents and academic qualifications were not attached to her application, as well as that of Erias Lukwago, another lawyer for Besigye who is also the mayor of Uganda’s capital city Kampala. “Rather than use these as reasons to decline my application, one would expect that the law council would have asked for whatever additional documents that it desired,” Karua, who holds the senior counsel title, wrote. “Mr Lukwago is not only a well-known personality as the Lord Mayor of the City of Kampala but also as a practising advocate running a law firm.” Karua said the Ugandan Law Council also questioned whether she brings “any special skill,” to which the former Kenyan justice minister responded: “With the greatest respect to your good selves, it is Dr Besigye’s constitutional right to appoint a lawyer/s of choice including a lead counsel of choice.” The council, Karua added, further accused her of presenting as a person holding a valid practising certificate in Uganda when she attended the December 2 court martial hearing of Besigye’s case. But she dismissed as untrue the account, saying Lukwago introduced her to the Ugandan court and said she awaited approval of her special license to practice law in Uganda. “It was on this basis that an adjournment was granted to the 10th of December. In the light of these facts, I take great exception to this unmerited accusation by yourselves which constitutes an attack on my character and integrity, and undermines the appearance of impartiality of the law council,” Karua said. “Your disparaging and personalized aspersions on my person and character, as well as the importation of extraneous matters, is regrettable and undermines the spirit of Jumuiya,” added Karua, a reference to the East African Community. Karua is leading a 50-member bench comprising representatives from well-known legal associations like the Pan-African Lawyers Union and the International Commission of Jurists in defending Besigye and his co-accused, Hajj Obeid Lutale. Besigye and Lutale were picked up in Nairobi by Ugandan agents on November 16, where Besigye had been invited to speak at the launch of Karua’s memoir, ‘Against the Tide’. They were driven to Uganda and locked up in a military jail. The duo, which has been in custody since November 20, is accused of illegal firearm possession and security-related offences, which critics of Ugandan President Yoweri Museveni’s government deem politically motivated. In the December 2 court martial hearing, Besigye and Lutale were charged with alleged illegal possession of two pistols and eight rounds of ammunition editor
HealthEquity Earnings Analysis: Q3 Recap
Gov Mohammed Signs N467bn 2025 State Budget Into LawPhase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen AMGN today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: Adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-ALL during the consolidation phase of multiphase therapy. CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1% in adults and pediatric patients one month or older. Relapsed or refractory CD19-positive B-ALL in adults and pediatric patients one month or older. In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: Adults with Philadelphia chromosome-negative CD19-positive relapsed or refractory B-ALL. Patients with Philadelphia chromosome-positive B-ALL should have failed treatment with at least two tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Adults with Philadelphia chromosome-negative CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1%. Pediatric patients aged 1 year or older with Philadelphia chromosome-negative CD19-positive B-ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. Pediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome-negative CD19-positive B-ALL as part of the consolidation therapy. BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® and treat with corticosteroids as recommended. Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® as recommended. Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Cytokine Release Syndrome (CRS): CRS, which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . The median time to onset of CRS is 2 days after the start of infusion and the median time to resolution of CRS was 5 days among cases that resolved. Closely monitor and advise patients to contact their healthcare professional for signs and symptoms of serious adverse events such as fever, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin (TBILI), and disseminated intravascular coagulation (DIC). The manifestations of CRS after treatment with BLINCYTO ® overlap with those of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Using all of these terms to define CRS in clinical trials of BLINCYTO ® , CRS was reported in 15% of patients with R/R ALL, in 7% of patients with MRD-positive ALL, and in 16% of patients receiving BLINCYTO ® cycles in the consolidation phase of therapy. If severe CRS occurs, interrupt BLINCYTO ® until CRS resolves. Discontinue BLINCYTO ® permanently if life-threatening CRS occurs. Administer corticosteroids for severe or life-threatening CRS. Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome: BLINCYTO ® can cause serious or life-threatening neurologic toxicity, including ICANS. The incidence of neurologic toxicities in clinical trials was approximately 65%. The median time to the first event was within the first 2 weeks of BLINCYTO ® treatment. The most common (≥ 10%) manifestations of neurological toxicity were headache and tremor. Grade 3 or higher neurological toxicities occurred in approximately 13% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Manifestations of neurological toxicity included cranial nerve disorders. The majority of neurologic toxicities resolved following interruption of BLINCYTO ® , but some resulted in treatment discontinuation. The incidence of signs and symptoms consistent with ICANS in clinical trials was 7.5%. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. There is limited experience with BLINCYTO ® in patients with active ALL in the central nervous system (CNS) or a history of neurologic events. Patients with a history or presence of clinically relevant CNS pathology were excluded from clinical studies. Patients with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO ® therapy. Monitor patients for signs and symptoms of neurological toxicities, including ICANS, and interrupt or discontinue BLINCYTO ® as outlined in the PI. Advise outpatients to contact their healthcare professional if they develop signs or symptoms of neurological toxicities. Infections: Approximately 25% of patients receiving BLINCYTO ® in clinical trials experienced serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO ® as needed. Tumor Lysis Syndrome (TLS), which may be life-threatening or fatal, has been observed. Preventive measures, including pretreatment nontoxic cytoreduction and on-treatment hydration, should be used during BLINCYTO ® treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO ® as needed to manage these events. Neutropenia and Febrile Neutropenia, including life-threatening cases, have been observed. Monitor appropriate laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO ® infusion and interrupt BLINCYTO ® if prolonged neutropenia occurs. Effects on Ability to Drive and Use Machines: Due to the possibility of neurological events, including seizures and ICANS, patients receiving BLINCYTO ® are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO ® is being administered. Elevated Liver Enzymes: Transient elevations in liver enzymes have been associated with BLINCYTO ® treatment with a median time to onset of 3 days. In patients receiving BLINCYTO ® , although the majority of these events were observed in the setting of CRS, some cases of elevated liver enzymes were observed outside the setting of CRS, with a median time to onset of 19 days. Grade 3 or greater elevations in liver enzymes occurred in approximately 7% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients. Monitor ALT, AST, gamma-glutamyl transferase, and total blood bilirubin prior to the start of and during BLINCYTO ® treatment. BLINCYTO ® treatment should be interrupted if transaminases rise to > 5 times the upper limit of normal (ULN) or if total bilirubin rises to > 3 times ULN. Pancreatitis: Fatal pancreatitis has been reported in patients receiving BLINCYTO ® in combination with dexamethasone in clinical trials and the post-marketing setting. Evaluate patients who develop signs and symptoms of pancreatitis and interrupt or discontinue BLINCYTO ® and dexamethasone as needed. Leukoencephalopathy: Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO ® , especially in patients previously treated with cranial irradiation and antileukemic chemotherapy. Preparation and administration errors have occurred with BLINCYTO ® treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose). Immunization: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO ® treatment, during treatment, and until immune recovery following last cycle of BLINCYTO ® . Benzyl Alcohol Toxicity in Neonates: Serious adverse reactions, including fatal reactions and the "gasping syndrome," have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions, because they may be less able to metabolize benzyl alcohol. Use the preservative-free preparations of BLINCYTO ® where possible in neonates. When prescribing BLINCYTO ® (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO ® (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway. Monitor neonatal patients receiving BLINCYTO ® (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO ® 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL. Embryo-Fetal Toxicity: Based on its mechanism of action, BLINCYTO ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO ® and for 48 hours after the last dose. Adverse Reactions The safety of BLINCYTO ® in adult and pediatric patients one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B-cell precursor ALL in consolidation (n=165) was evaluated in clinical studies. The most common adverse reactions (≥ 20%) to BLINCYTO ® in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea. Dosage and Administration Guidelines BLINCYTO ® is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm. It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose). INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy. Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission. Relapsed or refractory disease. Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References National Institute of Health. Cancer Stat Facts: Leukemia — Acute Lymphocytic Leukemia (ALL). Available at: https://seer.cancer.gov/statfacts/html/alyl.html . Accessed on October 28, 2024 . Terwilliger T, et al. Blood Cancer J . 2017;7(6):e577. American Cancer Society. What is Acute Lymphocytic Leukemia (ALL)? Available at: https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/what-is-all.html . Accessed on October 28, 2024 . Leukemia & Lymphoma Society. Acute Lymphoblastic Leukemia (ALL). Available at: https://www.lls.org/research/acute-lymphoblastic-leukemia-all . Accessed on October 28, 2024 . National Cancer Institute. Childhood Acute Lymphoblastic Leukemia (PDQ ® )–Patient Version. Available at: https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq . Accessed on November 19, 2024 . View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
South Korean authorities seek warrant to detain impeached presidentTesla releases new video of Optimus robot walking and it rings a bellThe No. 21 Syracuse Orange , led by quarterback Kyle McCord , face the Washington State Cougars , led by quarterback Zevi Eckhaus in the 45th annual DIRECTV Holiday Bowl on Friday, Dec. 27, 2024 (12/27/24) at Snapdragon Stadium in San Diego, Calif. How to watch: Fans can watch the game for free via a trial of DirecTV Stream or fuboTV . You can also watch via a subscription to Sling TV , which is offering half off your first month. — DirecTV Stream is offering $30 off on Entertainment with Sports Pack featuring NFL RedZone, BIG Ten Network and more. — fuboTV plans start at $79.99 per month, with $35 off your first month. — Sling TV is offering plans for as low as $23 for your first month Here’s what you need to know: What : Holiday Bowl Who : Syracuse vs. Washington State When : Friday, Dec. 27, 2024 Where : Snapdragon Stadium Time : 8 p.m. ET TV : FOX Live stream: fuboTV (free trial) and DirecTVStream (free trial) *** Here are the best streaming options for college sports: Fubo TV (free trial): fuboTV carries ESPN, FOX, ABC, NBC and CBS. DirecTV Stream (free trial) : DirecTV Stream carries ESPN, FOX, NBC and CBS. Sling TV - Sling TV carries ESPN, FOX, ABC and NBC. ESPN+ ($11.99 a month): ESPN+ carries college basketball games each week for only $11.99 a month. These games are exclusive to the platform. Peacock TV ($7.99 a month): Peacock is the exclusive home of 75-plus Big Ten men’s and women’s basketball games for the 2024-25 season. The streaming service will also broadcast several Big East men’s basketball and Atlantic 10 men’s women’s basketball contests. Paramount+ (free trial): Paramount Plus will live stream college football games airing on CBS this year. *** Here’s a college football story via the Associated Press: The first 12-team version of the College Football Playoff has reached the quarterfinals state, setting up some tantalizing matchups. Texas has also take over as the early betting favorite to win the national championship. Did the CFP committee get it right? The first-round games were held on campuses for the first time — before the games shift to bowl games for the quarterfinals and semifinals — and all four of the higher-seeded teams won comfortably. That led to fresh questions about the seeding process, and it’s all coming amid the early signing period and players flocking to the transfer portal . Here is what to know: There will be 11 games between Dec. 20 and the finale in Atlanta on Jan. 20, all broadcast nationally. The quarterfinals (times EST): Location: Rose Bowl, Pasadena, California, Jan. 1, 5 p.m. (ESPN) BetMGM College Football Odds: Ohio State by 2 1/2. What to know: The Buckeyes answered some critics with a blowout of Tennessee in the first round and now comes a rematch against the top-ranked Ducks. Oregon beat Ohio State by a single point in October in one of the season’s best games. The winner: Advances to Cotton Bowl semifinal to play Texas/Arizona State winner, Jan. 10. Location: Sugar Bowl, New Orleans, Jan. 1, 8:45 p.m. (ESPN) BetMGM College Football Odds: Georgia by 1 1/2. What to know: All eyes are on Georgia quarterback Carson Beck, whose arm injury could keep him sidelined. Notre Dame has been rolling since its only loss of the season but could find the going tougher against the Bulldogs. The Fighting Irish defense has been stout , too. The winner: Advances to Orange Bowl semifinal to play Boise State/Penn State winner, Jan. 9. Location: Fiesta Bowl, Glendale, Arizona, Dec. 31, 7:30 p.m. (ESPN) BetMGM College Football Odds: Penn State by 10 1/2. What to know: Is this the year Penn State finally gets back in a national title game? The Nittany Lions will spend the next week-plus focusing its defense on stopping Boise State running back and Heisman Trophy runner-up Ashton Jeanty. The winner: Advances to Orange Bowl semifinal to play Georgia/Notre Dame winner, Jan. 9. Location: Peach Bowl, Atlanta, Jan. 1, 1 p.m. (ESPN) BetMGM College Football Odds: Texas by 13 1/2. What to know: The Sun Devils have been one of the best stories in college football, defying predictions to win the Big 12. They will have to deal with the Longhorns' juggernaut running game, which was too much for Clemson in the opening round. The winner: Advances the Cotton Bowl semifinal to play Oregon/Ohio State winner, Jan. 10. With the quarterfinals set, Texas moved to the 3-1 favorite to win the national championship, according to BetMGM Sportsbook on Sunday. The rest of the odds: Ohio State (15/4), Oregon (4-1), Penn State (5-1), Georgia (11-2) and Notre Dame (6-1). Arizona State and Boise State were both listed as 60-1 longshots. A 13-member CFP selection committee spent the past six weeks evaluating the teams and then set the bracket on Dec. 8. The five highest-ranked conference champions were guaranteed spots in the field, no matter where they are ranked overall by the CFP; Clemson, for example, is ranked No. 16 in the CFP but was given the 12th and lowest seed as the fifth-highest ranked league champion. The top four seeds got a week off and an automatic trip to the quarterfinals. The CFP began with four teams in January 2015. It was expanded this year for the first time. Many believe it may expand again, perhaps as early as 2026. A lot: About $115 million is on the line in the playoff . Each conference gets $4 million for every team that makes the final 12, then another $4 million for those that make the quarterfinals. It means teams that earned byes are worth $8 million to their conferences without even playing a game. Teams that advance to the semifinals mean $6 million more for their conference, then another $6 million for making the final. The conferences all distribute the money differently. There’s also a $300,000 stipend per team that is academically eligible for the playoffs. Teams making the playoff get $3 million to cover expenses for each round, too. (The Associated Press contributed to this report) Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
South Korean authorities seek warrant to detain impeached President Yoon in martial law probeControversial red dye found in candy, drinks and snacks could soon be bannedPaedophile sent to prison for 'despicable' historic abuse
PARÍS (AP) — La Federación Francesa de Fútbol no intervendrá en la disputa entre Kylian Mbappé y su antiguo club, el Paris Saint-Germain, por salarios no pagados. El PSG solicitó a la federación que examinara la decisión del mes pasado de la comisión de apelaciones de la liga francesa de mantener una orden que obliga al club a pagar a Mbappé 55 millones de euros (60 millones de dólares). La federación indicó el viernes que su departamento legal encontró que “la solicitud de una evocación federal del caso presentada no cumplía con las condiciones requeridas”. El PSG no respondió de inmediato al anuncio. La comisión legal de la liga falló a favor de Mbappé, pero el PSG insistió en que no le debía dinero y apeló la decisión. Las partes fueron escuchadas nuevamente el 15 de octubre y el veredicto permaneció sin cambios. Mbappé previamente rechazó una oferta de mediación en su disputa con el PSG, diciendo que el club le debía el salario de tres meses y el último tercio de un bono de lealtad. Este verano se unió al Real Madrid como traspaso libre después de anotar un récord del PSG de 256 goles en siete años. El PSG argumentó que cuando Mbappé estuvo marginado antes de la temporada 2023-24 —siguiendo su decisión de no extender su contrato— llegaron a un acuerdo verbal en el que aseguraron que el jugador optó por renunciar a los bonos para volver al equipo. La relación de Mbappé con el PSG terminó en medio de profundas tensiones y algunos aficionados lo abuchearon en su último partido en casa en el Parc des Princes. El PSG se sintió decepcionado por Mbappé después de ofrecerle el contrato más lucrativo en la historia del club cuando firmó un nuevo contrato en 2022. Esta historia fue traducida del inglés por un editor de AP con la ayuda de una herramienta de inteligencia artificial generativa.Jimmy Carter's death sparks tributes, remembrances
True freshman Jackson Williams delivers 100-yard TD return, sparking Bison playoff victoryTAMPA, Fla. (AP) — Jake Evans scored for the career-high fifth consecutive game and the surging Montreal Canadiens beat the Tampa Bay Lightning 5-2 on Sunday night. Christian Dvorak, Joel Armia, Brendan Gallagher and Alex Newhook also scored to help the Canadiens win for the fifth time in six games. Sam Montembeault made 21 saves. Nikita Kucherov and Brandon Hagel scored for Tampa Bay. Jonas Johansson stopped 31 shots. Newhook opened the scoring on a one-timer midway through the first period. Hagel tied it 37 seconds into the second period, but Dvorak and Evans scored 5:54 apart in the period for a two-goal Montreal lead they would not relinquish. SABRES 4, BLUES 2 ST. LOUIS (AP) — Jason Zucker scored a tiebreaking power-play goal with 9:30 remaining and Buffalo notched their third straight victory by beating St. Louis. Jiri Kulich extended Buffalo’s lead with a breakaway goal that went between Blues goalie Jordan Binnington’s legs with 3:41 to play. Tage Thompson had a goal and an assist against his former team as the Sabres won in St. Louis for just the second time in 12 years to sweep the season series. Zucker had a goal and an assist, and Jack Quinn had two assists for Buffalo. Ukko-Pekka Luukkonen stopped 35 shots. Brayden Schenn and Nathan Walker scored for the Blues. Binnington had 12 saves. Buffalo scored on two of its first three shots, including its first of the game. DUCKS 5, OILERS 3 ANAHEIM, Calif. (AP) — Ryan Strome scored with 2:36 remaining as Anaheim rallied from a two-goal deficit in the second period to defeat Edmonton. Strome’s goal, his sixth of the season, originally wasn’t called, but it was reversed after a review. Strome’s shot was entirely over the goal line before Edmonton goalie Calvin Pickard could stop it with his skate. Mason McTavish added an empty-net goal. It is the first time since March 30, 2019, the Ducks have defeated the Oilers by more than one goal. Cutter Gauthier, McTavish and Robby Fabbri each had a goal and an assist. Drew Helleson also scored for Anaheim, which snapped a seven-game losing streak to Edmonton. Lukas Dostal made 20 saves. Leon Draisaitl had two goals and Connor McDavid two assists for the Oilers, who were 3-0-1 in their past four. Evan Bouchard also tallied a goal and Pickard stopped 27 shots. RED WINGS 4, CAPITALS 2 DETROIT (AP) — Patrick Kane reached the 1,300-point mark and Todd McLellan won for the first time as Detroit’s coach in their victory over Washington. Kane, who needed two points to reach that mark, had a power-play goal and assist during Detroit’s four-goal first period. Alex DeBrincat scored two goals and Lucas Raymond added another as the Red Wings snapped a four-game losing streak. Alex Lyon made 26 saves. McLellan replaced Derek Lalonde prior to Friday’s loss to Toronto . Alex Ovechkin scored for the second consecutive game after missing the previous 16 due to a fractured fibula . The Capitals star forward is 25 goals shy of passing Wayne Gretzky’s NHL record of 894 . Nic Dowd had the other Capitals goal. Charlie Lindgren made 23 saves but Washington remained one point behind first-place New Jersey in the Eastern Conference. PENGUINS 3, ISLANDERS 2 PITTSBURGH (AP) — Sidney Crosby broke Mario Lemieux’s Pittsburgh franchise career record for assists on Michael Bunting’s power-play goal and the Penguins beat New York. Crosby has 1,034 assists, good for 12th in NHL history. Only three players — Ray Bourque, Wayne Gretzky and Steve Yzerman — have more assists with a single team. The 37-year-old Crosby has played 1,310-regular-season games. Lemieux played 915. Evgeni Malkin added the deciding power-play goal in the third for Pittsburgh, which has 14 goals with the man advantage in its last 13 games. Anthony Beauvillier also scored to help the Penguins win for the seventh time in their last eight home games. Alex Nedeljkovic made 29 saves in his first start since Dec. 17. Kris Letang missed the game because of a lower-body injury, and defenseman Nathan Clurman made his NHL debut. Anders Lee and Bo Horvat scored third-period goals for the Islanders, who fell behind 3-0 before their rally fell short. Marcus Hogberg stopped 38 shots during his first start since April 28, 2021. GOLDEN KNIGHTS 3, FLAMES 0 LAS VEGAS (AP) — Brett Howden scored his 15th goal of the season and Ilya Samsonov stopped 31 shots as Vegas Golden defeated Calgary. Howden redirected defenseman Alex Pietrangelo’s shot from the top of the slot late in the second period and is now tied with Ivan Barbashev for the team lead in goals. Howden has scored a goal in four of the last five games. Victor Olofsson and Tanner Pearson also scored for the Golden Knights, who have shut out Calgary twice this season, beating them 5-0 on Oct. 28 . Dan Vladar made 34 saves for Calgary. The Golden Knights have now won six straight, the longest active win streak in the NHL, while improving to 25-8-3 on the year. They own a 13-2-1 record against Pacific Division opponents. SENATORS 3, WILD 1 ST. PAUL, Minn. (AP) — Josh Norris broke a tie on a power play with 7:18 left, Leevi Merilainen made 30 saves in his fifth NHL game and Ottawa beat Minnesota. Ottawa has won seven of its past nine games, while the Wild have lost five of their past seven. The Senators won in Minnesota for the first time since 2016. With starter Linus Ullmark and backup Anton Forsberg out with injuries, the Senators have been relying on Merilainen and Mads Sogaard since before the NHL holiday break. Frederick Gaudreau opened the scoring for Minnesota late in the first period. Ridly Greig tied it early in the second. Claude Giroux added an empty-netter. STARS 5, BLACKHAWKS 1 CHICAGO (AP) — Matt Duchene and Jamie Benn each had a goal and two assists, and Dallas beat Chicago. Jason Robertson, Evgenii Dadonov and Wyatt Johnston each had a goal and an assist for Dallas, which had lost three of four. Jake Oettinger made 24 saves. Chicago dropped its fourth consecutive game. It lost three of four in its season series against Dallas. Connor Bedard scored his 10th goal for the Blackhawks, and Arvid Soderblom made 26 stops. Next up for Bedard and company is the Winter Classic on Tuesday against St. Louis. Dallas grabbed control after Chicago forward Tyler Bertuzzi was ejected 8:11 into the second period. Bertuzzi was sent off for elbowing Stars forward Colin Blackwell in the face.
Polls close in Ghana's general election in the shadow of the worst economic crisis in a generationAn attempt by Rupert Murdoch to change who controls the future of his media empire has been blocked, according to reports in The New York Times. The newspaper claims a sealed court document accuses the 93-year-old of acting in "bad faith" by attempting to amend his family trust to benefit his eldest son, Lachlan. Currently, the trust passes control of the company equally among Mr Murdoch's four oldest children - Lachlan, James, Elisabeth and Prudence - after his death. But Nevada commissioner Edmund Gorman has rejected a bid to change the terms of the trust. Lachlan is head of Fox News parent Fox Corp and News Corp, which owns UK titles including The Sun and The Times. Mr Murdoch's proposed amendment would have blocked any interference by three of Lachlan's siblings, who are more politically moderate. US correspondent This is a storyline which could be straight out of the TV drama Succession, which many already suspected was heavily based on the Murdoch family. Rupert Murdoch, who is now 93, had been engaged in a lengthy court battle to try to hand over control of his media empire to his eldest son Lachlan when he dies. Lachlan, who is more politically conservative than his siblings, would in theory consolidate the right-wing stance of some parts of Murdoch's media empire - especially Fox News. Today a document obtained by the New York Times revealed the commissioner in the case has whole-heartedly rejected the plan to change his trust, calling it a "bad faith" deal from Murdoch and his eldest son. By bringing this case, Rupert Murdoch has made patently and painfully clear which of his children he favours. There is some fascinating detail of art imitating life as the court heard how Mr Murdoch's children had started secretly discussing a strategy for their father's death. They were prompted by an episode of Succession where media tycoon Logan Roy dies, throwing his family and empire into chaos. The reality is that there will no doubt be more family infighting, as Rupert Murdoch's lawyers say he is likely to appeal the judgment. Mr Gorman said the plan to change the trust was a "carefully crafted charade", according to The New York Times. More on Rupert Murdoch Murdoch-owned firm ends Rightmove takeover interest Rightmove to 'carefully consider' third bid by Murdoch-owned firm Succession battle: Why Rupert Murdoch and his children are fighting in court Related Topics: Rupert Murdoch The newspaper also described that, in the commissioner's opinion, it was an attempt to "permanently cement Lachlan Murdoch's executive roles" inside the empire "regardless of the impacts such control would have over the companies or the beneficiaries" of the family trust. Potentially, three of the heirs could out-vote a fourth, setting up a battle over the future of the companies. A spokesman for Mr Murdoch could not immediately be reached for comment. Follow our channel and never miss an update. Read more from Sky News: Bankers to scrutinise public sector spending Find out what is the 'Boxing Day bounce' But his lawyer, Adam Streisand, said they were disappointed with the ruling and intended to appeal, The New York Times reported. Sky News, which Mr Murdoch launched in the UK in 1989, is no longer part of his empire. At the end of 2018, Fox's film entertainment assets, such as The Simpsons and the Avatar film franchise, were sold to Disney - while the company's 39% stake in Sky was sold to Comcast .Colts coach Shane Steichen feeling heat after playoff elimination
NoneBy Ja'han Jones Over the years, the arguments against taking meaningful action against climate change have evolved from raising doubts about the science to claiming that rising temperatures might not be caused by human activity. Now President-elect Donald Trump is pushing it in an entirely new direction: Climate change is good, actually. Trump, who has mused that rising sea levels might lead to more beachfront property , announced recently that his pick for energy secretary is Chris Wright, a Big Oil CEO who has downplayed the risks of rising global temperatures and argued that climate change might actually be good for the world. These sentiments were revealed over the weekend in an article in The Wall Street Journal that featured various comments Wright made to the far-right platform PragerU, whose founder has bragged that he wants to "indoctrinate" American children with his politics. Per the WSJ: A fracking executive, Wright acknowledges that burning fossil fuels is contributing to rising temperatures. But he also says climate change makes the planet greener by increasing plant growth, boosts agricultural productivity and likely reduces the number of temperature-related deaths annually. “It’s probably almost as many positive changes as there are negative changes,” he told conservative media nonprofit PragerU last year, referring to climate change. “Is it a crisis, is it the world’s greatest challenge, or a big threat to the next generation? No.” For the record, the things Wright lists as positives of rising atmospheric carbon — like more plant growth and a boost in “agricultural productivity” — don’t always occur in climate change scenarios, and when they do, they aren’t always positive developments. (Read more on that here and here ). And contrary to Wright’s claim about temperature-related deaths, the Environmental Protection Agency reported this year that “dramatic increases in heat-related deaths are closely associated with the occurrence of hot temperatures and heat waves.” There are plenty more catastrophic scenarios that we know stem from climate change — circumstances that literally kill people and destroy properties and environments . Indeed, these are big threats to all generations that currently live on earth and any that wish to do so in the future. Reputable scientists around the world have concluded that over several decades, an average global temperature increase above 1.5 degrees C elsius (2.7 degrees F) could produce “irreversible” changes with “dangerous impacts for humanity. ” But Wright wants us all to see climate change through rose-colored glasses. “A little bit warmer isn’t a threat,” he said in the resurfaced PragerU interview. “If we were 5, 7, 8, 10 degrees [Celsius] warmer, that would be meaningful changes to the planet.” That sequence of numbers is particularly bizarre. Scientists believe the world is on track to get at least 3 degrees Celsius warmer than pre-industrial times, causing everything from destructive heat waves, wildfires and droughts to an ice-free Arctic Ocean to shifts in insect-born diseases . Six degrees is considered a doomsday scenario , with whole swaths of the Earth now uninhabitable. But Wright starts there, skipping up to an unimaginable 10 degrees of warming as maybe a problem in his offhand calculation. No one should be surprised that Trump is living up to his promise to let Big Oil executives live their wildest dreams if they gave money to his campaign. But arguing that climate change is good and the Earth could stand to warm a few more degrees is a new low, even by our already lowered standards. Ja'han Jones is The ReidOut Blog writer. He's a futurist and multimedia producer focused on culture and politics. His previous projects include "Black Hair Defined" and the "Black Obituary Project."
NoneCricket fans - and even Mitchell Starc - slam Marnus Labuschagne for his wild act during India's Boxing Day Test run chaseThis report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here . 24/7 San Diego news stream: Watch NBC 7 free wherever you are Rates to come down "gradually" U.S. Federal Reserve officials anticipate lowering interest rates "gradually" to "a more neutral stance," minutes of the Fed's November meeting showed. That's contingent on inflation continuing to "move down sustainably to 2 percent and the economy remaining near maximum employment" in line with Fed officials' expectations. Markets move past tariff threats Markets in the U.S. moved past President-elect Donald Trump's threat of more tariffs to scale new highs on Tuesday . The S&P 500 and Dow Jones Industrial Average closed at record highs. Asia-Pacific stocks were mixed on Wednesday . China's CSI 300 rose around 1.5%, while the country's industrial profits slumped by 10% from a year ago. Leadership reorganization in Samsung Samsung Electronics shuffled its leadership , the company announced on Wednesday. Jun Young-hyun is now Samsung's co-CEO and head of the memory chip arm — Jun issued an apology in October after the South Korean firm posted disappointing third-quarter guidance . Other changes in leadership include the president and chief technology officer of the foundry business. OpenAI gets $1.5 billion investment from Softbank Softbank is investing $1.5 billion in OpenAI , two people familiar with the matter told CNBC. As part of the deal, OpenAI is allowing current and former employees to sell shares up to roughly the same amount. Softbank had previously invested $500 million into OpenAI, but founder and CEO Masayoshi Son wanted a larger stake in it, according to one of the sources. [PRO] Data might show annual inflation ticking up The personal consumption expenditures price index is the Fed's preferred measure of inflation. The index for October will be released on Wednesday – and economists are expecting the headline number to tick up on an annual basis. Money Report Reddit targets international users for ad growth, teases bolstered search feature ‘Europe's Detroit' built a thriving car industry. Trump tariffs now threaten to unravel its success Even before Trump enters the White House, investors are already living in his world. That portends the influence Trump, as president, will have on the economy and markets. Upon Trump's election win, the so-called "Trump trade" has flourished , with risk assets in general on an upward trajectory. The market rally stalled for a while as investors digested the possible increase in inflation and drop in economic growth due to Trump's policies, but was jolted back to life after Trump picked Scott Bessent as his Treasury secretary. Most recently, Trump announced he would raise tariffs by an additional 10% on Chinese goods entering the U.S., and new tariffs of 25% on those from Mexico and Canada. Those three countries alone account for 43% of U.S. goods imports, wrote Goldman Sachs's chief economist Jan Hatzius. "The truth is that the drag from tariffs on growth is likely to outweigh tax cuts on the forecast horizon," said Gregory Daco, chief economist at EY-Parthenon. Automakers felt that sting most keenly because virtually all with a presence in the U.S. manufacture vehicles and parts in Mexico — 26% of auto imports into the U.S. are from Mexico, reported UBS. Shares of automakers GM , Stellantis and Ford Motor fell on reports of Trump's planned tariffs. That said, while individual stocks staggered, the broader market advanced. The S&P 500 rose 0.57% and the Dow Jones Industrial Average added 0.28%, with both indexes hitting fresh closing highs. The Nasdaq Composite climbed 0.63%. "Markets have become a lot more comfortable with the prospects of these tariffs being more bluster and more negotiating tactics than actual implementation," Jamie Cox, managing partner at Harris Financial, said. Posturing or not, it's likely Trump's proposed policies will sway the markets in the foreseeable future. — CNBC's Sarah Min, Alex Harring and Samantha Subin contributed to this report. Also on CNBC A new day, a new Trump policy for markets to digest Investors endorse Trump’s Treasury secretary pick Investors really like Trump’s Treasury secretary pick